Opinion|Videos|August 23, 2024
Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you incorporate proactive management strategies into your practice setting?
- What challenges have you faced when integrating proactive management strategies into the clinical practice setting?
- What tools/resources would be helpful in overcoming these?
Advertisement
Related to this article
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.
The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acid Reducers, Drug-Drug Interactions, and Setting Expectations for Response
2
How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy
3
Differentiation Syndrome, Cardiac Monitoring, and Administration of Menin Inhibitors
4
Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care
5